This core is a central resource to support clinical trials and physics research and MD Anderson Cancer Center (MDACC). Core B provides the following services: (1) support for proton and photon treatment planning;(2) quality assurance and delivery of treatments for patients enrolled in the clinical trials of Projects 1 and 2;(3) robustness evaluation and robust optimization of the proton treatment plans and treatment delivery for IMPT;(4) measurements for experimental verification and validation of computed dose distributions;(5) clinical physics support for credentialing for the trials described in Projects 1 and 2;and (6) dose computations with highly accurate methods including those employing Monte Carlo techniques. This core will also maintain, enhance and support the use of computational and optimization hardware and software infrastructure for treatment planning and QA for Projects 1 and 2 and for physics research in Projects 3 and 4. This core supports the mission of the NCI to improve the treatment and continuing care of cancer patients.

Public Health Relevance

This research aims to improve radiation treatment for cancer patients by improving our ability to direct the radiation at the tumor to spare adjacent normal tissue by using protons (charged particles) with intensity- modulated proton therapy. This can potentially improve cancer cure rates, reduce side effects, or both, depending on the clinical scenario. With an increasing number of proton centers in the United States and abroad, the research in this program project is increasingly important for public health.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Niedzielski, Joshua S; Yang, Jinzhong; Liao, Zhongxing et al. (2016) (18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. Int J Radiat Oncol Biol Phys 96:670-8
Gunn, G Brandon; Blanchard, Pierre; Garden, Adam S et al. (2016) Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys 95:360-7
Hall, David C; Makarova, Anastasia; Paganetti, Harald et al. (2016) Validation of nuclear models in Geant4 using the dose distribution of a 177 MeV proton pencil beam. Phys Med Biol 61:N1-N10
Unkelbach, Jan; Botas, Pablo; Giantsoudi, Drosoula et al. (2016) Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer. Int J Radiat Oncol Biol Phys 96:1097-1106
Niedzielski, Joshua S; Yang, Jinzhong; Stingo, Francesco et al. (2016) Objectively Quantifying Radiation Esophagitis With Novel Computed Tomography-Based Metrics. Int J Radiat Oncol Biol Phys 94:385-93
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2016) Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage 51:832-8
Underwood, Tracy; Paganetti, Harald (2016) Variable Proton Relative Biological Effectiveness: How Do We Move Forward? Int J Radiat Oncol Biol Phys 95:56-8
Unkelbach, Jan; Bussière, Marc R; Chapman, Paul H et al. (2016) Spatiotemporal Fractionation Schemes for Irradiating Large Cerebral Arteriovenous Malformations. Int J Radiat Oncol Biol Phys 95:1067-74
Taylor, Paige A; Kry, Stephen F; Alvarez, Paola et al. (2016) Results From the Imaging and Radiation Oncology Core Houston's Anthropomorphic Phantoms Used for Proton Therapy Clinical Trial Credentialing. Int J Radiat Oncol Biol Phys 95:242-8
Peeler, Christopher R; Mirkovic, Dragan; Titt, Uwe et al. (2016) Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. Radiother Oncol :

Showing the most recent 10 out of 15 publications